Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine combo shows promise in ovarian cancer fight

NCT ID NCT05920798

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial involves about 40 adults with recurrent ovarian, fallopian tube, or primary peritoneal cancer and aims to find the safest dose and measure how well the combination controls the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CARCINOSARCOMA PRIMARY PERITONEAL CARCINOSARCOMA RECURRENT FALLOPIAN TUBE CARCINOMA RECURRENT FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA RECURRENT FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA RECURRENT FALLOPIAN TUBE HIGH GRADE SEROUS ADENOCARCINOMA RECURRENT OVARIAN CARCINOMA RECURRENT OVARIAN CARCINOSARCOMA RECURRENT OVARIAN CLEAR CELL ADENOCARCINOMA RECURRENT OVARIAN ENDOMETRIOID ADENOCARCINOMA RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOMA RECURRENT PRIMARY PERITONEAL CARCINOSARCOMA RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA RECURRENT PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Arizona

    RECRUITING

    Scottsdale, Arizona, 85259, United States

    Contact Email: •••••@•••••

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Email: •••••@•••••

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.